There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Intellia Therapeutics (NTLA – Research Report), Rhythm Pharmaceuticals (RYTM – Research Report) and Kiniksa Pharmaceuticals (KNSA – Research Report) with bullish sentiments.
Intellia Therapeutics (NTLA)
In a report released yesterday, Greg Harrison from Bank of America Securities maintained a Buy rating on Intellia Therapeutics, with a price target of $80.00. The company’s shares closed last Thursday at $29.52.
According to TipRanks.com, Harrison is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Intellia Therapeutics with a $79.60 average price target.
See the top stocks recommended by analysts >>
Rhythm Pharmaceuticals (RYTM)
In a report released yesterday, Derek Archila from Wells Fargo maintained a Buy rating on Rhythm Pharmaceuticals, with a price target of $53.00. The company’s shares closed last Thursday at $43.31.
According to TipRanks.com, Archila is a 4-star analyst with an average return of
Currently, the analyst consensus on Rhythm Pharmaceuticals is a Strong Buy with an average price target of $49.71, representing a 15.5% upside. In a report released yesterday, Needham also maintained a Buy rating on the stock with a $50.00 price target.
Kiniksa Pharmaceuticals (KNSA)
In a report released yesterday, Geoff Meacham from Bank of America Securities reiterated a Buy rating on Kiniksa Pharmaceuticals, with a price target of $28.00. The company’s shares closed last Thursday at $19.13, close to its 52-week high of $20.65.
According to TipRanks.com, Meacham is a 4-star analyst with an average return of
Kiniksa Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $27.00, implying a 35.3% upside from current levels. In a report issued on January 2, Wedbush also maintained a Buy rating on the stock with a $25.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on NTLA:
- Intellia Therapeutics Highlights its Three-Year Strategic Priorities and Anticipated 2024 Key Milestones
- The Smid-cap biotech stocks to own in 2024, according to Bernstein
- Here are the Top 10 Female Analysts of 2023, According to TipRanks
- Crispr Therapeutics price target raised to $57 from $50 at RBC Capital
- Intellia Therapeutics files automatic mixed securities shelf
